Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Novavax Inc NVAX

Healthcare Biotechnology
Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company offers a differentiated vaccine platform that combines a recombinant protein approach, advanced nanoparticle technology and its patented Matrix-M adjuvant to enhance the immune response. It has one commercial program, for vaccines to prevent COVID-19, which includes Nuvaxovid prototype COVID-19 vaccine (NVX-CoV2373 or prototype vaccine) and Nuvaxovid updated COVID-19 vaccine (NVX-CoV2601 or updated vaccine) (collectively, COVID-19 Vaccine). The Company is advancing the development of other vaccine candidates, including its COVID19-Influenza Combination (CIC) vaccine candidate and additional vaccine candidates. Its COVID-19 Vaccine and its other vaccine candidates incorporate the Company’s proprietary Matrix-M adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response.


NDAQ:NVAX - Post by User

Novavax Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(259)
•••
Post by whytestockson Jul 10, 2023 1:00pm
167 Views
Post# 35533803

Novavax Inc. (NASDAQ: NVAX) Near the Top of Equities by Perc

Novavax Inc. (NASDAQ: NVAX) Near the Top of Equities by Perc
Breaking News: $NVAX Novavax Inc. (NASDAQ: NVAX) Near the Top of Equities by Percentage Gain on 7/10Novavax, Inc. (NASDAQ: NVAX) is one of today's top gainers. The company's shares are currently up 24.23% on the day to $8.98. Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address heal...NVAX - Novavax Inc. (NASDAQ: NVAX) Near the Top of Equities by Percentage Gain on 7/10

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities